IQ4I research & Consultancy Published New Report on Next Generation Sequencing (NGS) Global Market

SAN DIEGO - Nov. 6, 2014 - PRLog -- IQ4I Research & Consultancy published a new report on “Next Generation Sequencing (NGS) Global Market  – Forecast To 2020”  analyzes and studies the major market drivers & Opportunities, Restraints & Threats in North America, Europe, Asia-Pacific and Rest of the World

IQ4I’s Report Contains 122 market data tables and27figures spread through 304 pages and an exhaustive TOC on “Next Generation Sequencing Global Market [Products (Instruments & Consumables, Services and Work Flow Products), Technology (Targeted Resequencing, Whole Exome Sequencing, RNA Sequencing, Whole Genome Sequencing, ChiP sequencing, De novo sequencing, and Methyl Sequencing), End Users (Academic Research, Hospitals & Clinics, Biotech/Pharma and Others) Applications {Clinical (Oncology, Genetic Screening, Infectious Diseases and Others), Non-Clinical (Oncology, Genetic Screening, Infectious Diseases, Drug & Biomarker discovery, Epidemology, Agriculture and Others)}, Region (North America, Europe, APAC and RoW)]

Early buyers will receive 10% customization of your requirements.

The global Next Generation Sequencing market is expected to reach $4.89 billion by 2020. This report analyzes the NGS market not only in terms of market revenue ($ Million) for all segments but also provides key volume analysis of NGS sample runs performed by various technologies, platforms and end users/laboratories. The study would help in identifying the opportunities to commercial NGS bioinformatics software, and service providers, whose market is currently fragmented and is in the budding stage.

The NGS market is mainly driven by factors such as reduced cost and high speed of NGS technology, increased use in the clinical segment, new application areas of NGS and switch over from microarrays to NGS. However, the standardization of NGS for clinical use, complexity in data interpretation, shortage of skilled labor and dependence of grants and funding for NGS infrastructure are restraining the market growth. The demand for NGS technology especially in drug discovery and development, growth of personalized medicine using NGS, increased medical spending along with the rise in incidences of chronic diseases have provided the opportunity for the market to grow at a faster pace.  At the same time, ethical and legal issues related to huge data storage and interpretation poses a threat to the market.

In 2013, the North America accounted for the largest share of 42.4% in 2013 and also registered a strong CAGR during the forecast period. Asia-Pacific (APAC) region is expected to grow at the highest CAGR from 2014 to 2020. Among the Asia-Pacific countries, China is considered to be a genome hub led by the vast network of BGI (Beijing Genomics Institute) which is the largest sequencing centre in the world. This trend in China is also influencing other Asian countries around China such as India, Singapore and Malaysia.

The reasons for the highest growth in the APAC region is the huge demand for NGS, next generation sequencing trend in hospitals especially for Non-Invasive Prenatal Test (NIPT), cheap sequencers, better bioinformatics tool for data interpretation, presence of data analysis firms, increased medical spending and awareness. RNA sequencing is predominantly used in this region followed by targeted resequencing and whole exome sequencing. Academic research institutes are the largest end users in the region but hospitals and clinics segment is expected to grow faster.

Illumina Inc (U.S.) is the largest player in the NGS market with a share of XX%, followed by Thermo Fisher Scientific (U.S.) and Roche (Switzerland) accounting for XX% and XX% shares respectively in 2013. The NGS market is consolidated, with major players accounting for more than 90% market share in 2013. Top ten major players include are Illumina Inc (U.S.), Thermo Fisher Scientific (U.S.), Hoffmann-La Roche Ltd (Switzerland), Pacific Biosciences (U.S.) Agilent Technologies (U.S.), BGI (Beijing Genomics Institute) (China), Qiagen (Netherlands), Biomatters Ltd (New Zealand), and Genomatix Software GmbH (Germany).

Reasons for buying this report:

·         Market assessment of all segments and sub segments of NGS market

·      In-depth value analysis of various segments such as NGS technologies, platforms and type of laboratories.

·         Volume information on Samples, platforms and service providers

·         Regulatory scenario across the globe

·         Major players profiles and their competitive landscaping